Navigation Links
Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors

Abstract #7083; June 2, 2007; 8:00am-12:00pm; McCormick Place Convention Center, S Hall A2

An oral dosage formulation of azacitidine: A pilot pharmacokinetic study - R. Ward, Pharmion; Abstract #7084; June 2, 2007; 8:00am-12:00pm; McCormick Place Convention Center, S Hall A2

Response to azacitidine in patients with myelodysplastic syndrome with marrow fibrosis - R. Juvvadi, Western Penn, Pennsylvania; Abstract #7089; June 2, 2007; 8:00am-12:00pm; McCormick Place Convention Center, S Hall A2

(Back to top)

Contact details

Breanna Burkart or Anna Sussman

Directors, Investor Relations and Corporate Communications

Pharmion Corporation

Tel: +1 720 564 9144 or +1 720 564 9143

Tara May

On-site media contact

Tel: +1 303 646 7832

About Vidaza

On May 19, 2004, Vidaza became the first drug approved by the FDA for the treatment of patients with Myelodysplastic Syndromes (MDS). The FDA approved Vidaza, the first in a new class of drugs called demethylation agents, for treatment of all five MDS subtypes, which include both low-risk and high-risk patients. These subtypes include: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) if accompanied by neutropenia or thrombocytopenia or requiring transfusions; refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).

Vidaza is believed to exert its antineoplastic effects by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. The concentration of azacitidine required for maximum inhibition of DNA methylation in vitro does not cause major suppression of DNA synthesis. Hypomethylation may restore normal function to genes that are critical for differentiation and proliferation. The cytotoxic effects of azacitidine cause the death of rapidly dividing cells, including can
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:12/15/2009)... A Harvard medical expert internationally recognized as ... PGA Tour,s decision last month to suspend Doug ... him as having the medical condition hypogonadism ... is "unreasonable, unfair and discriminatory." ,, Hypogonadism ... testosterone levels, often referred to informally as ...
(Date:12/15/2009)... 15 Fenwal Inc., a global medical ... safety and availability, announced today that the U.S. ... to market InterSol ® platelet additive solution. ... is a specialized product used in combination with ... blood component used to prevent or treat bleeding. ...
(Date:12/15/2009)... 15 Reportlinker.com announces that a ... its catalogue: ,, Boehringer Ingelheim GmbH: ... ,, Introduction ,, This analysis ... Boehringer Ingelheim in the Rx pharmaceutical sector. ... pipeline analysis and assessment of financial performance, ...
Breaking Medicine Technology:Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 2Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 3Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 4Fenwal Receives FDA Approval for New Solution Used to Store Donated Blood Platelets 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 3Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 4Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 5Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 6Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 7Hendrick Health System Deploys Sentillions Tap 26 Go Advanced Authentication Solution 52269 1Hendrick Health System Deploys Sentillions Tap 26 Go Advanced Authentication Solution 52269 2Hendrick Health System Deploys Sentillions Tap 26 Go Advanced Authentication Solution 52269 3Ovary removal may increase lung cancer risk 52266 1Ovary removal may increase lung cancer risk 52266 2New Jersey Dietetic Association Names Ketchums Jaime Schwartz Young Dietitian of the Year 52263 1New Jersey Dietetic Association Names Ketchums Jaime Schwartz Young Dietitian of the Year 52263 2New Jersey Dietetic Association Names Ketchums Jaime Schwartz Young Dietitian of the Year 52263 3
... conducted in MDS - Vidaza therapy confers highly significant 9.4 month ... conventional care regimens, - Two year overall survival rate of 50.8% for ... ... Pharmion Corporation,(Nasdaq: PHRM ) today announced the submission of a MAA ...
... a.m. ET Today, SOUTH SAN FRANCISCO, Calif., ... ) today announced that the Independent Data,Monitoring Committee ... Phase 3,clinical trials of GVAX immunotherapy for prostate ... recommended that the study continue.,This event-driven interim analysis ...
Other Medicine Technology:Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 2Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 3Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 4Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 5Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 6Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 7Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer 2Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer 3Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer 4
(Date:12/15/2009)... Team In Training (TNT), The Leukemia & Lymphoma ... program, has reached a remarkable milestone of raising ... patient services. ,, For more than 21 years, ... training program, preparing amateurs and seasoned athletes to ... cycle ride or hike adventure. Through the program,s ...
(Date:12/15/2009)... Dec. 15 North American application activity ... November year-over-year, according to the MIB Life ... applications over the past three months have lifted ... of -1.6%, to flat at November,s close, -0.1%. ... interest in the benefits available from life insurance," ...
(Date:12/15/2009)... service, such as tutoring children, can help older ... to a study led by researchers at the ... functional magnetic resonance imaging (fMRI), the researchers found ... made gains in key brain regions that support ... daily life. The study is the first of ...
(Date:12/15/2009)... still too early to say that phthalates ... Dec. 15 (HealthDay News) -- Common chemicals found ... the abnormal growth of breasts in boys, preliminary ... a prominent medical journal for pediatricians, adds fuel ... whose safety has been questioned by some scientists. ...
(Date:12/15/2009)... goes up within a week of getting news, ... -- Emotional stress can put newly diagnosed prostate ... and suicide, a new study has found. , ... with prostate cancer between 1961 and 2004. Of ... event within a year of cancer diagnosis and ...
Breaking Medicine News(10 mins):Health News:$1 Billion - For Charity! 2Health News:$1 Billion - For Charity! 3Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 2Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 3Health News:For older adults, participating in social service activities can improve brain functions 2Health News:Breast Growth in Boys Might Be Linked to Plastics Chemical 2Health News:Breast Growth in Boys Might Be Linked to Plastics Chemical 3
... Biomoda, Inc. (OTC,Bulletin Board: BMOD) ( http://www.biomoda.com ... detection testing and other cancer diagnostic technology,announced today ... to provide a range of clinical services including,protocol ... "Averion is a global clinical research organization ...
... the University of Iowa College of Nursing, and two ... for a four-year $1.2 million grant to ensure that ... for elders with mental health issues. , The three ... the Geropsychiatric Nursing Collaborative, are in the UI College ...
... IPF Awareness Week on Capitol Hill Drives,Efforts to ... SAN JOSE, Calif., Oct. 4 The Coalition ... of its fifth,annual National IPF Awareness Week, which ... the critical need to fund new research into,idiopathic ...
... The following is a,statement regarding Microsoft,s announcement of new ... It is encouraging that companies like Microsoft, Google and ... products and systems,that people can use to manage their ... suit. Having ready access to your own,health information -- ...
... 4, 2007 MedImmune, Inc. today announced results from ... Society of America (IDSA) 45th Annual Meeting adding to ... RSV is a viral pathogen that produces annual ... manifests cold-like symptoms in healthy children, it can prove ...
... Health Coaching Service,with HealthVault,s Best-Of-Breed Health ... and Compatibility with Other Related Devices,and ... LiveHealthier,announced today the compatibility of its ... HealthVault, the newly launched consumer health,platform. ...
Other Medicine News:Health News:Biomoda and Averion International Announce Agreement for Clinical Services 2Health News:CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget 2Health News:CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget 3Health News:CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget 4Health News:Statement Regarding Microsoft's Announcement of New Services to Help People Store Their Health Information Online 2Health News:Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results 2Health News:LiveHealthier Announces Its Health and Wellness Coaching Solution for Employer Groups is Now Compatible With Microsoft HealthVault 2
... is based upon the physiological form ... motion segment unit. Kinematics and morphology ... biomechanical and anatomical aspects of the ... implant components utilizing proven implant materials: ...
3D Cranial is the most widely used surgical navigation software. Navigate with confidence and ease with displayed Zone of Accuracy and several fully automated features. 3D Cranial offers seamless int...
Designed for use during surgical procedures under fluoroscopy. A very practical unit, the frames superior design eliminates problems associated with imaging....
Low temp, micro fine tip, patented Aaron RAM cauteries....
Medicine Products: